col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


31 Results       Page 1

 [1] 
Informa UK (Taylor & Francis): Expert Opinion on Biological Therapy
  original article Date Title Authors   All Authors
1 [GO] 2024―Aug―01 Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19 Arturo Casadevall, Scott McConnell, Daniele Focosi
2 [GO] 2024―Mar―04 Emerging anti-spike monoclonal antibodies against SARS-CoV-2 Eloy E. Ordaya, Raymund R. Razonable
3 [GO] 2023―Dec―15 Intravenous immunoglobulin as a potential treatment for long COVID Matthew W McCarthy
4 [GO] 2023―Jul―08 Optimizing the use of vilobelimab for the treatment of COVID-19 Matthew W McCarthy
5 [GO] 2023―Jun―15 Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions Raymund R Razonable
6 [GO] 2023―May―06 Interferon lambda as a potential treatment for COVID-19 Matthew W McCarthy
7 [GO] 2023―Apr―19 REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT Raveendra KR, Chirag Rathod, Rahul Darnule, Subramanian Loganathan, Sarika Deodhar, Radhika A, et al. (+5)
8 [GO] 2023―Jan―03 Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity Ileana García-Silva, Dania O Govea-Alonso, Sergio Rosales-Mendoza
9 [GO] 2022―Oct―15 Original antigen sin and COVID-19: implications for seasonal vaccination Matthew W McCarthy
10 [GO] 2022―Aug―05 Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis Paolo Gisondi, Davide Geat, Francesco Bellinato, Giampiero Girolomoni
11 [GO] 2022―May―23 Therapeutic monoclonal antibodies for COVID-19 management: an update Vivek P Chavda, Riddhi Prajapati, Disha Lathigara, Bhumi Nagar, Jay Kukadiya, Elrashdy M Redwan, et al. (+3)
12 [GO] 2022―Apr―29 Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease Lucia Trotta, Massimo Pancrazi, Emanuele Bizzi, Enrico Tombetti, Ruggiero Mascolo, Giada Pallini, et al. (+4)
13 [GO] 2021―Sep―24 Do we need bamlanivimab? Is etesevimab a key to treating Covid-19? Sheila A Doggrell
14 [GO] 2021―Aug―06 Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents Marina Talamonti, Marco Galluzzo
15 [GO] 2021―Apr―22 Immunomodulatory Extracellular Vesicles: An alternative to cell therapy for COVID-19 Ashim Gupta, Shivaji Kashte, Sachin Kadam, Manu Gupta, Hugo C. Rodriguez, Anish G. Potty, et al. (+2)
16 [GO] 2021―Apr―09 A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19 Suresh Kumar, Rosemarie De Souza, Milind Nadkar, Randeep Guleria, Anjan Trikha, Shashank R. Joshi, et al. (+4)
17 [GO] 2021―Feb―06 Immune Checkpoint Inhibition in COVID-19: Risks and Benefits Parmida Sadat Pezeshki, Nima Rezaei
18 [GO] 2021―Jan―28 Tocilizumab for the treatment of COVID-19 Mario Fernández-Ruiz, Francisco López-Medrano, José María Aguado
19 [GO] 2020―Nov―20 Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic: Risk Analysis from the PSO-BIO-COVID Observational Study Marina Talamonti, Marco Galluzzo, Andrea Chiricozzi, Pietro Quaglino, Gabriella Fabbrocini, Paolo Gisondi, et al. (+30)
20 [GO] 2020―Nov―07 A Comprehensive Review on Sarilumab in COVID-19 Sajad Khiali, Afra Rezagholizadeh, Taher Entezari-Maleki
21 [GO] 2020―Aug―31 The effect of drugs used in rheumatology for treating SARS-CoV2 infection Fabiola Atzeni, Elisabetta Gerratana, Manuela Giallanza, Laura La Corte, Valeria Nucera, Gianfranco Miceli, et al. (+2)
22 [GO] 2020―Aug―12 Host-directed therapies: a potential solution to combat COVID-19 Piyush Baindara, Sonali Agrawal, Santi M. Mandal
23 [GO] 2020―Aug―08 Immunotherapy for SARS-CoV-2: Potential Opportunities Mehrnoosh Pashaei, Nima Rezaei
24 [GO] 2020―Aug―03 Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects Khan Sharun, Ruchi Tiwari, Mohd. Iqbal Yatoo, Shailesh Kumar Patel, Senthilkumar Natesan, Jaideep Dhama, et al. (+4)
25 [GO] 2020―Jul―23 Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications Subramanian Loganathan, Sandeep N. Athalye, Shashank R. Joshi
26 [GO] 2020―Jun―26 COVID-19 Pneumonia and Immune-Related Pneumonitis: critical issues on differential diagnosis, potential interactions and management Marco Russano, Fabrizio Citarella, Andrea Napolitano, Emanuela Dell’Aquila, Alessio Cortellini, Francesco Pantano, et al. (+3)
27 [GO] 2020―Jun―08 Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era Marco Galluzzo, Lorenzo Tofani, Luca Bianchi, Marina Talamonti
28 [GO] 2020―May―14 Tocilizumab: From the Rheumatology Practice to the Fight Against COVID-19, a virus infection with multiple faces Miguel A. González-Gay, José Mayo, Santos Castañeda, José M. Cifrián, José Hernández-Rodríguez
29 [GO] 2020―May―08 Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity? Leticia Moreno-Fierros, Ileana García-Silva, Sergio Rosales-Mendoza
30 [GO] 2020―Apr―24 Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia Pietro Gentile, Aris Sterodimas
31 [GO] 2020―Apr―06 Will plant-made biopharmaceuticals play a role in the fight against COVID-19? Sergio Rosales-Mendoza
 [1] 

31 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec